Dosimetric characterization of TheraSeed and AgX100 include Monte Carlo and experimental studies conducted in accordance with the AAPM Task Group 43 update (TG43U1). For references, please visit the AAPM Sealed Source Device Registry: http://rpc.mdanderson.org/RPC/home.htm
TheraSeed: http://rpc.mdanderson.org/rpc/BrachySeeds/TheraSeed_model_200.htm
AgX100: http://rpc.mdanderson.org/rpc/BrachySeeds/AgX100.htm
1Rivard, et al., “Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations”, Med Phys. 31, 663-674, (2004)
Content intended for the USA. Indications may vary in different countries; please either consult the appropriate IFU or your local distributor.